1-(3-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)azetidin-1-yl)-2-(3,5-dichlorophenylamino)ethanone | 1374239-62-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(3-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)azetidin-1-yl)-2-(3,5-dichlorophenylamino)ethanone
• 英文别名: 2-(3,5-dichloroanilino)-1-[3-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)azetidin-1-yl]ethanone
• CAS: 1374239-62-9
• 化学式: C₁₆H₁₅Cl₂N₇O
• 分子量: 392.247
• InChiKey: ZVNGYDQQXFTSRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  98.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Viral vector manufacture
  申请人：Sementis Limited

  公开号：US10544397B2

  公开（公告）日：2020-01-28

  This present invention relates to a modified mammalian cell in which the genome of the cell is modified to comprise a sequence encoding CP77 under the control of a promoter such that the modified cell line sustains propagation of a poxvirus that is less able or unable to propagate in the unmodified cell.

  本发明涉及一种改造过的哺乳动物细胞，在这种细胞中，细胞的基因组经过改造，包含一个在启动子控制下编码 CP77 的序列，从而使改造过的细胞系能够维持痘病毒的繁殖，而这种痘病毒在未经改造的细胞中繁殖能力较弱或无法繁殖。
• VIRAL VECTOR MANUFACTURE
  申请人：Sementis Limited

  公开号：EP3063278B1

  公开（公告）日：2018-02-28
• HETEROCYCLIC TYROSINE KINASE INHIBITORS
  申请人：Biogen MA Inc.

  公开号：US20170027956A1

  公开（公告）日：2017-02-02

  The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.
• US9273028B2
  申请人：——

  公开号：US9273028B2

  公开（公告）日：2016-03-01
• [EN] HETEROCYCLIC TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE HÉTÉROCYCLIQUES
  申请人：BIOGEN IDEC INC

  公开号：WO2012058645A1

  公开（公告）日：2012-05-03

  The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.